FemHealth Ventures

Anchored in New York and built around a single conviction, FemHealth Ventures funds therapeutics, medical devices, and digital health platforms designed specifically around women’s biology rather than retrofitted from male-default research. The firm operates as a generalist within women’s health, weighing reproductive medicine and pharma-grade therapeutics alongside service-driven and software-enabled platforms. That focus is narrow by category but broad by modality, which is unusual: the same partner conversations span clinical trial design, regulatory pathways, and consumer adoption curves. Limited public information is available on portfolio composition or named partners, so the firm’s public posture is best read through its stated category mandate rather than a detailed track record.

The fund concentrates on Seed and Series A rounds, deploying initial checks in the $1M to $5M range. That sizing positions FemHealth Ventures as a meaningful early backer rather than a passive participant, with capacity to lead or co-lead small institutional rounds. The firm is United States-based with a New York headquarters, and while geographic scope is not formally disclosed, the stage and check profile suggest a primary focus on US-domiciled companies with meaningful clinical or commercial exposure to American payers and regulators.

For founders, the operating premise is straightforward: bring a defensible thesis on a women’s health problem that has been underserved by general healthcare investors, and be ready to discuss clinical evidence, reimbursement strategy, and commercial channel as a single integrated plan. The firm’s category specialization implies pattern recognition on women’s health-specific risks such as off-label dynamics, OB-GYN adoption behavior, and FDA pathways for sex-specific indications. Founders should expect direct, category-fluent diligence rather than generalist healthcare framing.